Please assess the completion status of the following clinical trial:

Trial Title: Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients are candidates to receive both proton beam and sorafenib~2. Patients with tumor burden that exceeds San Francisco criteria~Exclusion Criteria:~1. Patients who are candidates for surgical resection~2. Patients with tumor burden within Milan and/or San Francisco criteria~3. Patients who have contraindication to receive proton~4. Patients with contraindication to receive sorafenib including uncontrolled hypertension, coumadin treatment and prior intolerability to the drug~5. Patients treated previously by any locoregional treatment~6. Patients with prior liver transplant~7. Patients with child class C~8. Patients with model for end-stage liver disease (MELD) score of \> 25~9. Patients with other comorbid diseases that may impact survival~10. Patients with ongoing alcohol intake~11. Patients with active sepsis~12. Patients with gastrointestinal bleeding within a week~13. Patients unwilling to sign informed consent form~14. Patients with history of noncompliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Proton Beam Radiotherapy plus Sorafenib (Type: ACTIVE_COMPARATOR): A combination of radiation therapy (proton) to kill tumor cells as well as Sorafenib which is a study drug administered to patients to stop tumor growth.
- Sorafenib (Type: ACTIVE_COMPARATOR): Sorafenib is an oral pill taken daily to inhibit tumor growth at the cellular level.

Based on this trial design, predict the completion outcome and termination type (if applicable).